4/15/2022 4:03:26 PM Could the Specter of March-In Rights Finally Impact Drug Pricing Reform? By Kristen Riemenschneider Joshua Samuel On March 24, 2022 a group of public interest organizations filed a petition urging the Department of Health and Human Services (“HHS”) to...
1/24/2022 7:00:24 PM Is it time for big biopharma companies to rethink the use of federal funding for R&D? By Kristen Riemenschneider This article was originally published in STAT on January 18, 2022. I have been negotiating with representatives of the federal government...
8/30/2021 6:57:55 PM Trying cases during trying times: Recommendations for the bench and bar By Eric Bruce Jennifer Loeb With the recent and unfortunate surge of the delta variant, it’s clear that judges and lawyers will need to adapt to new ways of trying...
3/16/2021 12:00:00 AM Digital Bank Robbers: Sanctions Risks for Digital Currency Service Companies By Nabeel Yousef Stephanie Brown Cripps Amy Cattle Andrew Bulovsky +1 more... Show less On February 17, 2021, the US Department of Justice (DOJ) unsealed charges against three North Koreans accused of conspiring to steal and...
1/30/2021 12:00:00 AM Risk Factor Disclosures for the Recovery Era By Valerie Ford Jacob Doru Gavril Sarah Solum Drew Liming +1 more... Show less You Mastered the COVID-19 Risk Disclosures; But Are You Ready for the Recovery? It’s early 2021. With a new year comes a new Form 10-K. ...